This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Seattle Genetics Announces Clinical Leadership Appointments

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that Jonathan Drachman, M.D., has been promoted to Chief Medical Officer and Executive Vice President, Research and Development. Dr. Drachman joined Seattle Genetics in November 2004, serving most recently as Senior Vice President, Research and Translational Medicine. In this new role, he will lead the company’s clinical development and regulatory affairs teams, in addition to his continued oversight of research and translational medicine. The company also announced that it has promoted Eric Sievers, M.D., to Senior Vice President, Clinical Development. Dr. Sievers will be responsible for clinical development and life cycle management activities for ADCETRIS® (brentuximab vedotin), and many of the company’s clinical development programs.

“Jonathan has been a vital member of the management team for several years, demonstrating his passion for patients and a creative, science-based approach to research and drug development,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “This promotion allows him to bring his vision and leadership to a broader scope of activities, including our ADCETRIS clinical development program as well as our robust clinical and preclinical antibody-drug conjugate (ADC) pipeline.”

Prior to joining Seattle Genetics, Dr. Drachman was Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle, where he remains a Clinical Associate Professor of Medicine. He also served as Senior Investigator in the Division of Research and Education and Medical Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center. Dr. Drachman received a B.A. in Biochemistry from Harvard University and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine and fellowship in Medical Oncology at the University of Washington.

Eric Sievers joined Seattle Genetics in July 2006, and has focused primarily on directing, planning and executing clinical development activities for ADCETRIS. Previously, Dr. Sievers served as Medical Director at Zymogenetics (acquired by Bristol-Myers Squibb in 2010). His academic research focused on improving treatment outcomes for patients with acute myeloid leukemia, including clinical development of an anti-CD33 ADC. Dr. Sievers performed his training in pediatric hematology and oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, and served on the faculty of both institutions for more than a decade. Dr. Sievers received both a B.A. in Biology and an M.D. from Brown University.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs